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Background: Neuroblastoma is a pediatric cancer of neural crest origin. Despite aggressive treatment, mortality
remains at 40 % for patients with high-risk disseminated disease, underscoring the need to test new combinations
of therapies. In murine tumor models, our laboratory previously showed that T cell-mediated anti-tumor immune
responses improve in the context of lymphopenia. The goal of this study was to incorporate lymphodepletion
into an effective immune therapy that can be easily translated into neuroblastoma standard of care. Based on
the lymphodepleting effects of cyclophosphamide, we hypothesized that cyclophosphamide would synergize
with the TLR9 agonist, CpG oligodeoxynucleotide (ODN), to produce a T cell-mediated anti-neuroblastoma effect.
Methods: To test this hypothesis, we used the AgN2a aggressive murine model of neuroblastoma. Mice bearing
subcutaneous tumors were treated with cyclophosphamide followed by treatment with tumor cell lysate mixed
with CpG ODN injected at the tumor site.
Results: Subcutaneous neuroblastoma regressed only in mice that were treated with 100 mg/kg cyclophosphamide
prior to receiving treatments of tumor lysate mixed with CpG ODN. The anti-neuroblastoma response was
T cell-mediated. Synergy between cyclophosphamide and the tumor lysate/CpG ODN treatment influenced the
production of anti-tumor CD8 T cell effectors, and dendritic cell homeostasis. For clinical consideration, an allogeneic
tumor lysate was used effectively with this protocol to eliminate AgN2a tumor in vivo.
Conclusion: Synergistic immune modulating effects of cyclophosphamide and a treatment containing tumor cell
lysate and CpG ODN provide T cell-mediated anti-tumor activity against murine neuroblastoma.
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Neuroblastoma is a pediatric cancer of neural crest origin
that accounts for 12 % of all pediatric cancer deaths.
Patients with localized neuroblastoma in the adrenal
medulla or paraspinal ganglia respond well to conventional
therapy with an overall survival of greater than 95 %.
Unfortunately, nearly half of all neuroblastoma patients
have high-risk disseminated disease for which overall
survival is poor [1, 2]. Treatment with myeloablative
chemotherapy followed by autologous stem cell transplant
and isotretinoin has improved survival, but there is still* Correspondence: bjohnson@mcw.edu
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unless otherwise stated.greater than 60 % mortality. Based on a 2-year 20 %
increase in event-free survival, anti-GD2 disialoganglioside
antibody in combination with interleukin-2 (IL-2) and
granulocyte colony stimulating factor (GM-CSF) has been
added to standard of care protocols [3]. This increase in
survival is proof of principle that immune therapy can be
effectively administered for treatment of refractory disease.
However, there is a need to test other therapies to further
improve survival.
The goal of immune therapy is to destroy tumors through
the activation of immune cells, including T lymphocytes. In
a murine model of aggressive neuroblastoma (AgN2a), we
previously observed a T cell-mediated immune response
resulting in elimination of established AgN2a [4]. In this
model, mice were administered a cell-based tumor vaccinel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CD80, CD86 and CD137L. Importantly, this cell-based
tumor vaccine failed to eliminate established tumor unless
it was administered in the context of lymphodepletion. The
best anti-neuroblastoma response occurred when the
vaccine was delivered following hematopoietic stem
cell transplantation (HSCT) with an adoptive transfer
of tumor antigen sensitized lymphocytes depleted of
CD25+ cells [5].
In a multiple myeloma model, we observed a T cell-
mediated anti-tumor response when mice were given
checkpoint blockade in the context of lymphodepletion [6].
Notably, lymphodepletion followed by anti-PD-L1 or anti-
PD-1 administration was ineffective at producing a T cell
mediated anti-tumor response for a PD-L1-negative mur-
ine neuroblastoma. These data emphasize that anti-tumor
immune therapy must be tailored specifically toward
tumor characteristics in order to be effective. Yet, these
previous studies demonstrated that lymphocyte activa-
tion in the context of lymphodepletion appears to be
essential to enhance anti-tumor immunity.
For the current study, our aim was to test the anti-tumor
efficacy of CpG oligodeoxynucleotide (ODN) 1826, a class
B toll-like receptor 9 (TLR9) agonist, (henceforth
referred to as CpG) in the context of non-myelablative
chemotherapy. Cyclophosphamide (Cy) was delivered as a
lymphodepleting agent prior to administration of a tumor
cell lysate plus CpG (lysate/CpG) treatment. Tumor
lysate was combined with CpG in an effort to augment
antigen capture by antigen presenting cells. The agents
used in this study are clinically translatable and can
be tested for synergy with existing standard of care and
other immune modulating therapies for the treatment of
neuroblastoma.
Innate immune cells integrate a variety of signals from
the microenvironment that allow them to mature and
promote an adaptive anti-tumor immune response. Since
tumor microenvironments are generally immunosuppres-
sive, the maturation and/or activation of innate immune
cells can be suppressed, contributing to immune tolerance
to tumor. TLR9 ligands are synthetic unmethylated bacter-
ial CpG motifs that have been under study as adjuvants to
activate immune cells. Engagement of TLR9 ligands with
the intracellular endosomal TLR9 receptor mimics the
“danger signal” that is activated by bacterial DNA. This
results in activation and maturation of innate immune cells
such as natural killer (NK) cells [7], macrophages [8] and
dendritic cells (DCs) [9]. Upon maturation of innate cells
there is an up-regulation of cellular mechanisms that pro-
mote a Th1 adaptive immune response, including efficient
antigen processing and presentation [10].
Cyclophosphamide also has immune modulating effects.
Studies have shown that Cy induces Th1 cytokine produc-
tion and differentiation of Th17 cells [11, 12], transientlyreduces T regulatory cell numbers [13], induces type I
interferon [14], and enhances DC activation and DC-T cell
priming [15–18]. The lymphopenia induced by Cy is
transient and is associated with in vivo proliferation and
expansion of antigen-specific T cells [19].
CpG has been shown to synergize with the immune
modulating effects of Cy to enhance antitumor immunity.
The administration of the human-specific class B
CpG ODN 2006, in combination with Cy improved
survival in mice with rhabdosarcoma [20]. In this model,
the enhanced anti-tumor response was T cell dependent.
In addition, administration of CpG ODN 1826 with agonist
anti-CD40 antibody in combination with vincristine, Cy
and doxorubicin chemotherapy produced anti-tumor
effects mediated by effector M1 macrophages [21].
Based on the known immune modulating mechanisms of
Cy and CpG, we hypothesized that Cy would synergize
with lysate/CpG treatment to produce a T cell-mediated
anti-neuroblastoma response. The results demonstrate
that administration of Cy prior to lysate/CpG treatment is
necessary to promote a T cell-mediated regression of
established neuroblastoma.
Results
Lysate/CpG provides protection from live tumor
challenge and delays progression of established tumor
To begin, a tumor challenge model was used to rapidly
assess the relevance of using tumor lysate and CpG for
the treatment of neuroblastoma. Mice received 2 weekly
hind flank subcutaneous (sc) treatments of tumor lysate,
CpG or a combination of lysate/CpG (Fig. 1a). Ten days
later mice were challenged with 105 live AgN2a cells ex-
pressing firefly luciferase (AgN2a FF) at the treatment
site. Mice were followed for tumor growth and eutha-
nized when growth exceeded 250 mm2. All of the mice
that received only lysate died from tumor burden by
48 days following tumor inoculation (Fig. 1a). Of the mice
that received CpG only or lysate/CpG, 5 of 8 and 11
of 18, respectively, survived for 60 days without any
palpable tumor mass at the inoculation site. These
data show that a treatment containing CpG or lysate/
CpG induced an immune response to AgN2a tumor cells
capable of preventing tumor formation in some tumor
challenged mice.
It has been reported that DCs do not spontaneously
cross-present necrotic cell antigen to CD8 T cells [22].
Therefore, in order to optimize antigen capture by anti-
gen presenting cells, lysate/CpG versus CpG alone was
used as treatment in a therapeutic model. To test if the
lysate/CpG treatment would eliminate existing tumor,
mice were first inoculated sc with 105 AgN2a FF cells.
Nine days after tumor inoculation mice received either
no treatment or 4 weekly peri-tumoral sc treatments of
lysate/CpG (Fig. 1b). In addition to lysate/CpG, some
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Fig. 1 Lysate/CpG treatment protects from live tumor challenge and delays growth of existing neuroblastoma. a Groups of mice (6–8 per group)
received 2 weekly hind flank sc treatment of AgN2a tumor lysate, CpG, AgN2a lysate mixed with CpG or no treatment. Mice were challenged
with 105 AgN2a FF cells 10 days after the last treatment and were followed for tumor growth. Mice were euthanized when tumor growth
exceeded 250 mm2. The graph represents 1 of 2 separate experiments. The CpG only group was tested once with 8 mice per group. b Mice
received 105 AgN2a FF cells sc in the hind flank. Beginning 9 days after tumor inoculation, mice received no treatment or 4 weekly treatments of
lysate/CpG. In addition to lysate/CpG, some mice received 200 μg of anti-Thy1.2 antibody ip on days 14, 18, 22 and 26. Mice were followed for
survival and euthanized when tumor size reached 250 mm2. The graph represents combined data from 2 experiments with 5 mice per group.
Data was analyzed for statistical significance using the log-rank (Mantel-Cox) test
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cell depleting anti-Thy1.2 antibody (200 μg). The anti-
Thy1.2 antibody was administered on days 14, 18, 22 and
26 according to the schedule in Fig. 1b. T cell depletion
was confirmed in all anti-Thy1.2 treated mice by flow cy-
tometric analysis of CD4 and CD8 T cells in peripheral
blood on day 21 (data not shown). All of the mice that re-
ceived no treatment or lysate/CpG with anti-Thy1.2 were
euthanized for tumor burden by 27 days after tumor in-
oculation (Fig. 1b). Of the mice that received the lysate/
CpG treatment, tumor growth was significantly delayed,
and 1 of 10 mice had no palpable tumor mass 50 days
after tumor inoculation. Since the anti-tumor effect wasabrogated when mice received the anti-Thy1.2 antibody,
the delay in tumor progression appeared to be T cell-
mediated.
Cy and lysate/CpG induces IFN-γ producing
tumor-specific CD8 T cells
Cy is a widely used standard of care chemotherapeutic
that has immune modulating effects [23]. Low dose Cy
is know to transiently deplete T regulatory (T regs) cells
[13], as well as induce a lymphopenia that contributes
to homeostatic proliferation of lymphocytes. Since our
previous data has shown that anti-tumor immunity is
enhanced in the context of lymphopenia, Cy was
Fig. 2 CD8 T cell IFN-γ is increased in mice that receive Cy and lysate/CpG. a Groups of mice were treated (no treatment, Cy only, Cy and CpG,
Cy and lysate or Cy and lysate/CpG) according to the schedule. On day 22, spleens from 3 mice per group were harvested and pooled. b CD8 T
cells were purified by immunomagnetic cell separation and 105 were incubated overnight with 105 AgN2a stimulator cells. IFN-γ production was
analyzed per ELISPOT assay. Background signal (T cells only with no tumor cell stimulators) was subtracted from the experimental values. The graph
represents data from 1 to 2 independent experiments. Data was analyzed for statistical significance using one-way ANOVA
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cording to the schedule in Fig. 2a. To determine which im-
mune modulating agent(s) were most effective in producing
anti-tumor effector T cells, mice were treated with Cy only,
Cy and CpG, Cy and lysate or Cy and lysate/CpG. On day
22, spleens were harvested and pooled according to treat-
ment groups. CD8 Tcells were incubated with AgN2a target
cells and analyzed for IFN-γ secretion in ELISPOT assays.
There was a significant increase in IFN-γ producing tumor-
specific splenic CD8 T cells when mice were treated with Cy
and lysate/CpG>Cy and lysate > Cy and CpG>Cy only
(Fig. 2b). These data suggest that administration of Cy
synergizes with lysate/CpG to produce anti-AgN2a T cell ef-
fectors. Since the Cy and lysate/CpG treatment provided the
best CD8 T cell effector response, this treatment group was
further tested for in vivo efficacy.
Existing neuroblastoma regresses when cyclophosphamide
is administration prior to lysate/CpG treatment
To test if the Cy and lysate/CpG treatment was thera-
peutic in reducing or regressing existing neuroblastoma,
mice were inoculated sc with 105 AgN2a FF to generate a
tumor burden and were treated according to the schedule
in Fig. 2a. For this experiment, different doses of Cy wereused to determine if dose had any effect on anti-tumor
synergy with lysate/CpG. Cy was administered at
doses of 50, 75 or 100 mg/kg on days 7 and 8 after
tumor inoculation. One day after the second Cy treat-
ment, some mice began 4 weekly peri-tumoral sc
treatments of lysate/CpG and all mice were followed
for tumor growth (Fig. 3). For the mice that received
50 mg/kg Cy, and lysate/CpG there was a delay in
tumor growth as compared to Cy only treated mice;
however, all of the mice eventually died from tumor
burden. For mice treated with 75 mg/kg Cy and
lysate/CpG, tumor was eliminated in 3 of 10 treated
mice. Mice that received 75 mg/kg Cy and lysate/
CpG plus anti-Thy1.2 all died from tumor burden.
These data suggest that the anti-tumor immune re-
sponse is T cell mediated. The best anti-tumor effect
occurred when mice were treated with 100 mg/kg Cy and
lysate/CpG. With this treatment, 6 of 10 mice experienced
tumor regression with no palpable tumor. In some mice
tumor regression was confirmed by biophotonic imaging
showing loss of tumor luciferase activity (Additional file 1:
Figure S1). For the mice treated with Cy only there was a
progressive delay in tumor burden when the dose was in-
creased from 50 to 100 mg/kg. These data suggest that Cy
75 mg/kg Cy

























































Cy lysate/CpG + anti-Thy1.2
Fig. 3 Cy administered prior to lysate/CpG treatment eliminates existing
neuroblastoma. Groups of mice received ip Cy in doses of 50, 75 or
100 mg/kg followed by either no treatment or 4 weekly treatments of
lysate/CpG according to the schedule in Fig. 2a. In addition to lysate/
CpG, some mice received 200 μg of anti-Thy1.2 antibody ip on days 14,
18, 22 and 26. Mice were followed for survival and euthanized when
tumor size reached 250 mm2. Each graph represents data combined
from 2 separate experiments with 5 mice per group. Data was analyzed
for statistical significance using the log-rank (Mantel-Cox) test
Gershan et al. Journal for ImmunoTherapy of Cancer  (2015) 3:24 Page 5 of 11alone has dose-dependent anti-tumor effects (Additional
file 2: Figure S2). Together, these data suggest that
there is anti-tumor synergy when Cy is administered
prior to lysate/CpG, and the synergy appears to depend
on the Cy dose. Since Cy at 100 mg/kg offered the best
anti-tumor effect when combined with lysate/CpG treat-
ment, 100 mg/kg was used in subsequent experiments.Lysate/CpG enhances TEM expansion and activation and
differentiation of DCs during Cy-induced homeostatic
expansion
Cy administered prior to lysate/CpG treatment was required
to produce an anti-neuroblastoma response. Since Cyproduces a transient lymphopenia, we sought to
characterize T cell and DC subsets during homeostatic pro-
liferation following Cy administration. We were specific-
ally interested in determining if the anti-neuroblastoma
effects of lysate/CpG treatment correlated with expansion
of T cells and dendritic cell subsets that promote both
adaptive and innate immune responses. To determine the
effects of treatment on T cell depletion and reconstitution,
splenic T cells were analyzed before Cy and several time
points following Cy administration. As expected, numbers
of CD4+ T cells, CD8+ T cells and CD4+FoxP3+ T regula-
tory cells were reduced 3 days after Cy administration
(day 11 post tumor inoculation) (Fig. 4a). At 14 days after
Cy administration (day 22 after tumor inoculation), there
was greater expansion of CD8+ T cells and CD4+ T regula-
tory cells in mice treated with Cy and lysate/CpG as com-
pared to Cy only. Using the average absolute number of
splenic CD8+ T cells and CD4+ FoxP3+ T regulatory
cells (calculated from 4 to 14 mice), the CD8+:CD4
+FoxP3+ T cell ratio was 3.3 for mice treated with Cy and
5.7 for mice treated with Cy and lysate/CpG. The in-
creased ratio of CD8 T cells to T regulatory cells in mice
treated with Cy and lysate/CpG correlated with an im-
proved anti-tumor response as compared to mice treated
with Cy only. Of interest, the percentage of CD4+ and
CD8+ T effector memory (TEM; CD44
+CD62L−) cells was
greater in mice treated with Cy and lysate/CpG > Cy
only > no treatment. By 14 days after Cy administration,
there was also a significant increase in the percentage of
Ki67+ splenic CD4+ and CD8+ T cells in mice that received
Cy and lysate/CpG as compared to Cy only (Fig. 4b). To-
gether these data suggest that lysate/CpG enhances prolifer-
ation of CD4 and CD8 T cells and augments the expansion
of CD8 effector T cells during Cy-induced homeostatic
proliferation.
CpG has been reported to enhance DC differentiation
and the capacity of DCs to activate T cells [9, 24, 25]. To
determine the effect of lysate/CpG on DC differentiation
during Cy-induced homeostatic expansion, CD3−CD11c+
DCs were analyzed for expression of CD11b, CD8α, B220
and the activation marker, MHC class II. The absolute
number of splenic DCs was reduced 3 days (day 11 after
tumor inoculation) following Cy administration (Fig. 4c).
The recovery of DC subsets was analyzed 14 days follow-
ing Cy administration (day 22 after tumor inoculation). In
the spleen, there was a significant increase in percentage
of migratory CD11b-B220+CD8α− and a decrease in
immature CD11b+B220+CD8a− DCs when mice received
lysate/CpG during the Cy-induced homeostatic expansion
(Fig. 4d). During Cy-induced homeostatic proliferation,
the percentage of CD11c+ MHC class II+ (IAK) DCs in the
spleen and draining lymph node was increased in mice
that received Cy and lysate/CpG (Fig. 4e). Together,
these data indicate that during Cy-induced homeostatic
























































































































































































































































Fig. 4 (See legend on next page.)
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Fig. 4 Immune cell analysis. Mice were divided into treatment groups (no treatment, Cy only or Cy and lysate/CpG) and treated according to the
schedule in Fig. 2a. a Spleens were harvested and pooled from 5 mice in each treatment group on days 4, 11 and 22 of the treatment schedule.
The depletion and recovery of CD4+ T cells, CD8+ T cells, CD4+FoxP3+ T cells, CD4+ CD44+ CD62L− effector memory (EM) and CD8+ CD44+
CD62L− EM cells is shown over time. b On day 22, spleens were harvested and pooled from 4 to 5 mice in each treatment group. CD3+ CD4+ or
CD3+ CD8+ cells were analyzed for intracellular Ki67 expression. c–e Spleens were pooled from 3 to 5 mice in each treatment group. c Absolute
number of CD3− CD11c+ DCs on day 11 of the treatment schedule in Fig. 2a. d The percentage of spleen CD3− CD11c+ dendritic cells
differentially expressing CD11b, B220 and CD8α on day 22. e The percentage of CD3−CD11c+ DC expressing MHC class II (IAk+) on day 22. Graphs


























































Fig. 5 Cy and allogeneic lysate/CpG treatment is effective in
regressing AgN2a tumor. a Groups of mice were treated with either
Cy and AgN2a lysate/CpG or Cy and 9464D allogeneic lysate/CpG
according to the protocol in Fig. 2a. Mice were followed for tumor
growth and were euthanized when tumor reached 250 mm2. Nine
of 17 AgN2a lysate/CpG and 8 of 15 9464D lysate/CpG treated mice
did not have palpable tumor 100 days post tumor inoculation. Data
was analyzed for statistical significance using the log-rank (Mantel-Cox)
test. The graph represents data combined from 2 separate
experiments. The Cy and CpG control group was tested once
with 5 mice per group showing statistical significance. b Groups
of AgN2a-bearing mice were treated with CpG and (1) irrelevant
splenocyte lysate, (2) control 5T33 multiple myeloma tumor lysate,
(3) allogeneic 9464D neuroblastoma tumor lysate, or (4) syngeneic
AgN2a neuroblastoma tumor cell lysate according to the schedule in
Fig. 2a. On day 22 after tumor inoculation, bone marrow was harvested
and pooled from 3 mice in each group. CD8 T cells were purified by
immunomagnetic cell separation and 105 were incubated overnight
with 105 AgN2a stimulator cells. IFN-γ production was analyzed per
ELISPOT assay. Background signal (T cells only with no tumor cell
stimulators) was subtracted from the experimental values. The graph
represents data from 1 to 2 independent experiments. Data was
analyzed for statistical significance using the Student’s t test
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skew DC differentiation.
Treatment with Cy and an allogeneic lysate/CpG
regresses AgN2a tumor
To produce a more clinically translatable treatment
protocol, anti-AgN2a efficacy was tested using an allogeneic
lysate. Mice were treated with Cy, and an allogeneic 9464D
neuroblastoma lysate/CpG or Cy and AgN2a lysate/CpG
according to the schedule in Fig. 2a. Mice were followed for
tumor growth and euthanized when tumors reached
250 mm2. Similar to previous results, 8 of 15 of the mice
that received Cy plus AgN2a lysate/CpG were tumor-
free 100 days following tumor cell inoculation (Fig. 5a).
Importantly, 9 of 17 mice treated with Cy plus the 9464D
allogeneic lysate were also tumor free. All of the control
mice (untreated, treated with Cy, Cy and CpG or
AgN2a lysate/CpG only) died. One control mouse
that received Cy only did not develop tumor. Tumor-
bearing mice treated with CpG and the neuroblast-
oma 9464D lysate generated AgN2a-specific T cells as
shown in the IFN-γ ELISPOT in (Fig. 5b). For the
ELISPOT, AgN2a cells were used as stimulator cells.
Discussion
Our previous studies showed that the anti-tumor effi-
cacy provided by immune-based therapies increases
when the therapy is administered in the context of
lymphopenia [4–6, 26, 27]. In this study, we found that
the T cell-mediated anti-tumor efficacy of a tumor lysate/
CpG treatment was dependent on pre-treatment with
lymphodepleting cyclophosphamide chemotherapy (Fig. 3).
The synergistic effects of Cy and lysate/CpG were required
to induce tumor elimination as Cy alone or lysate/CpG
alone was ineffective at eliminating tumor. Cy produced a
transient lymphodepletion of T cells that reached a nadir
within 2 days of administration (Fig. 4a). There was a
gradual increase in splenic T cell absolute numbers by
14 days after Cy administration. The T cells expanding
under Cy-induced lymphopenic conditions expressed
TEM activation markers and this was enhanced in
mice that received both Cy and lysate/CpG. Others
have reported an expansion of T effectors secondary
to immunization with peptide and CpG [28]. These data
Gershan et al. Journal for ImmunoTherapy of Cancer  (2015) 3:24 Page 8 of 11suggest that homeostatic expansion of anti-tumor T
cells is induced by lymphopenia and further augmented
by lysate/CpG.
Anti-tumor T cell memory was tested in mice that had
regressed AgN2a when treated with Cy and lysate/CpG.
When mice were re-challenged with 105 live AgN2a,
there was a delay in tumor progression as compared
to untreated mice. However, mice eventually died of
tumor progression, indicating a lack of effective anti-tumor
memory (data not shown). In a previous study, a T
cell-mediated anti-rhabdomyosarcoma effect occurred
when mice were treated with Cy and the human 2006
class B CpG; T cell memory was also not observed in
this model [20]. The mechanisms responsible for T
cell memory are unknown, but the combination of
lymphodepletion with high dose tumor antigen and CpG
may be a combination that drives T cell differentiation
toward a terminally differentiated effector phenotype and
less toward a memory phenotype [29]. Our data and the
data of others indicate that despite the T cell dependent
anti-tumor response induced by Cy and lysate/CpG,
additional immune modulation is required to generate
anti-tumor T cell memory.
Synergy of Cy with tumor vaccines/treatments to
produce a T cell dependent anti-tumor effect has been
previously reported [30]. Data in the current study
provides insight into the contributions of Cy and lysate/
CpG towards producing an anti-tumor response. Both
Cy and CpG can modulate innate immunity. Reports of
Cy-induced immune modulation include lymphopenia-
induced recovery of immature DCs [14, 17, 30], alteration
of DC subsets in secondary lymphoid organs [15, 17] and
transient depletion of T regulatory cells [13]. Cy has
also been shown to mobilize bone marrow DCs and
promote expansion of immature DCs in peripheral blood
[17, 19, 30]. It has been proposed that lymphopenia-
induced myelopoiesis resets myeloid and DC homeostasis.
In the current study, Cy induced a depletion of DCs and
changed the balance of DC subsets in the spleen. There
was a significant increase in splenic CD11b+ B220− CD8α−
migratory DCs, and lysate/CpG synergized with Cy by
further increasing the percentage of splenic CD11b+ B220−
CD8α− migratory DCs. There was also a significant de-
crease in immature non-migratory CD11b− B220+ CD8a−
DCs in mice treated with Cy as compared to untreated
mice (Fig. 4d). Expression of MHC class II on CD11c+ DCs
is a marker of maturation and is required for efficient
antigen presentation. Cy alone induced a significant
increase in the percentage of splenic CD11c+ DCs express-
ing MHC class II (Fig. 4e). Lysate/CpG synergized with Cy
to further increase the percentage of CD11c+ spleen cells
expressing MHC class II. In the dLN there was a significant
increase in the numbers of cells expressing MHC class II
only in mice that received Cy and lysate/CpG. Thesedata suggest that the T cell-mediated anti-neuroblastoma
response may be influenced by the synergy of Cy with
lysate/CpG to reset DC homeostasis and maturation.
The biologic activities of Cy are dose dependent [31]. At
200 mg/kg, bone marrow dendritic cell precursors are
depleted [30]. In this study, the best anti-tumor synergy
occurred when 100 mg/kg of Cy was given prior to
lysate/CpG (Fig. 3). When mice were treated with Cy
only, tumor progression was delayed as the dose increased
(Additional file 2: Figure S2). In fact, at 100 mg/kg, 1 of 10
mice did not form a tumor. These data indicate that Cy
may have some direct cytolytic effect on the tumor cells.
The induction of an efficient immune response requires
both antigen access and DC maturation [22]. It is possible
that treatment with Cy provided tumor antigen by inducing
tumor cell cytolysis. However, due to evidence that DCs do
not spontaneously cross-present necrotic cell antigen to
CD8 T cells [22], our protocol was designed to include de-
livery of tumor antigen in the form of tumor cell lys-
ate. In Cy treated mice, the inclusion of lysate mixed
with CpG was required to produce the greatest num-
ber of anti-AgN2a CD8 T effector cells (Fig. 2b). In
other studies, tumor lysate plus CpG was required to
produce anti-tumor responses. A murine anti-glioma re-
sponse occurred when lysate was combined with mouse
CpG 2006 or human CpG 7909 [32]. Also, T cell func-
tion was inhibited when chemotherapy with CpG-ODN
and anti-CD40 were administered without supplemental
tumor antigen [21].
One of the goals of this study was to generate a T
cell-mediated anti-neuroblastoma response using easily
translated immune modulating agents. Cy is a standard of
care chemotherapeutic, and in clinical trials, CpG ODNs
have been show to be safe when administered as cancer
adjuvants [33]. Autologous tumor lysate is difficult to
obtain, but it is possible that antigen cross-reactivity
provided by allogeneic tumor lysate can substitute as an
antigen source. The advantage of using an allogeneic
tumor lysate is that it can be prepared as an “off the
shelf” agent. In this treatment protocol, treatment
with an allogeneic neuroblastoma lysate produced CD8 T
cells that were activated in the presence of AgN2a tumor
cells (Fig. 5b).
Conclusions
In summary, the synergistic immune modulating effects
of Cy and a lysate/CpG treatment provide T cell-mediated
anti-tumor activity against murine neuroblastoma. Both
Cy and lysate CpG alter the homeostatic expansion of
T cells and modulate DC homeostasis. The synergistic im-
mune modulation provided by Cy with lysate/CpG
may boost anti-tumor immunity when combined with
standard of care therapy. However, an optimal therapy
for neuroblastoma will, most likely, require a combination
Gershan et al. Journal for ImmunoTherapy of Cancer  (2015) 3:24 Page 9 of 11of chemotherapy and immune activating agents (such as
lysate/CpG) in addition to immune therapies that promote
anti-tumor T cell memory.
Methods
Mice
Male A/J mice, 6–8 weeks of age, were purchased from
the Jackson Laboratory. All mice were housed in the
Medical College of Wisconsin (MCW) Biomedical
Resource Center (Milwaukee, WI), which is accredited by
the American Associated for Accreditation of Laboratory
Animal Care (AALAC). All animal studies were approved
by the Medical College of Wisconsin Institutional Animal
Care and Use Committee.
Tumor cells
An aggressive AgN2a cell line, was produced in our
laboratory through sequential in vivo passage of Neuro-2a
(ATCC) in mice as previously described [33]. To
generate established tumors, AgN2a cells were injected
subcutaneously (sc) into the hind flank of strain A/J mice.
Tumor growth was monitored by standard caliper
measurements. Mice were considered moribund and
euthanized when tumors reached 250 mm2. For some
studies, AgN2a cells with stable expression of firefly
luciferase (AgN2a FF) were used (pcDNA3.1/firefly
luciferase was provided by Dr. Michael Dwinell, Medical
College of Wisconsin). The 9464D N-myc overexpressing
cell line was developed in the laboratory of Dr. Jon
Wigginton at the National Cancer Institute (NCI). The
9464D cell line was derived from a spontaneous tumor
that arose in a C57BL/6 N-myc transgenic mouse that was
developed by Dr. William A. Weiss (University of California,
San Francisco, CA).
Biophotonic imaging
Mice inoculated with firefly expressing AgN2a cells
were ip injected with 50 mg/kg D-luciferin. Luciferase
activity was detected using the Xenogen IVIS imaging
system (PerkinElmer, Waltham, MA). Regions of interest
(ROI) surrounding the tumor bioluminescent signal
were drawn using LIVING IMAGE software Version
2.6 (Xenogen). Results are reported as ROI total pho-
ton flux.
Lysate/CpG treatment
Tumor lysate was made from the AgN2a (syngeneic)
or 9464D (allogeneic) tumor cell lines. Cells were
washed twice with phosphate buffered saline (PBS)
and 5 × 106 were suspended in 0.2 ml PBS. For lysis,
cells were placed in liquid nitrogen for 60–90 s
followed by incubation in a 37 °C water bath for 3–4 min.
This freeze/thaw cycle was repeated four times. The lysate
was centrifuged at 300 × g for 5 min to pellet cell debris.The cell debris was removed by filtering the lysate through
a 0.22 μm filter. The lysate was stored at −80 °C until
further use.
Class B CpG-ODN 1826 (5′ TCCATGACGTTCCTGA
CGTT 3′) was purchased from TriLink Biotechnologies
(San Diego, CA). Mice received 50 μg CpG suspended in
either 0.2 ml of PBS (CpG only) or in 0.2 ml of tumor cell
lysate (lysate/CpG).
Antibodies and flow cytometry
Cells were stained with combinations of the following
monoclonal antibodies: Anti-CD44 (1 M7), anti-IAk
(11–5.2) and anti-B220 (RA3-6B2) (BD Biosciences
Pharmingen). Anti-CD3 (145-2C11), anti-CD4 (RM4-5),
anti-CD8a (53–6.7), anti-CD62L (MEL-14), anti-CD11c
(N418), anti-CD11b (M1/70), anti-FoxP3 (FJK-16 s), and
anti-Ki67 (eBioscience). 7-aminoactinomycin D (7AAD)
was added to each sample as a viability marker. All
stained cells were analyzed using a BD LSR II Flow
Cytometer System (BD Biosciences, San Diego, CA).
The data was analyzed using Flow-Jo software (Tree
Star, Inc, San Carlos, CA).
T cell purification
Spleens or draining lymph nodes (dLN) were isolated,
pooled from several mice, and processed into single cell
suspensions. Cells were labeled with anti-CD8 conju-
gated magnetic microbeads (Miltenyi Biotec, Auburn,
CA) and were sorted by positive selection using a
Miltenyi automated immunomagnetic sorter (autoMACS).
The CD8 T cell purity was ~85 %. To increase the
purity of CD8 T cells, cells were stained with anti-
CD8 antibodies and sorted by flow cytometry using a
FACSAria cell sorter (BD Biosciences, San Diego, CA).
Sorting by flow cytometry increased the T cell purity
to >99 %.
IFN-γ ELISPOT assay
The numbers of AgN2a-specific IFN-γ producing CD8
T cells were determined by an enzyme-linked immuno-
sorbent spot (ELISPOT) assay (BD Bioscience (San Diego,
CA). For this assay, purified T cells were plated in a 96 well
plate with 105 live AgN2a target cells. After 24 h, IFN-γ
production was quantified using a Cellular Technology
Limited (CTL) ImmunoSpot Analyzer (CTL Analyzers,
LLC, Cleveland, OH).
Statistics
ELISPOT and flow cytometry data was analyzed by
one-way ANOVA. Survival curves were compared
using the log-rank (Mantel-Cox) test. All statistical
analyses were calculated using GraphPad Prism 5.0a
software (GraphPad, San Diego, CA). P values <0.05 were
considered as significant.
Gershan et al. Journal for ImmunoTherapy of Cancer  (2015) 3:24 Page 10 of 11Additional files
Additional file 1: Figure S1. Tumor detection using biophotonic
imaging of luciferase expressing tumor cells. Mice were ip injected with
the firefly luciferase substrate D-luciferin (50 mg/kg) and imaged for firefly
luciferase biophotonic signal using the Xenogen IVIS imaging system.
The figure shows serial images of tumor signal in one mouse from each
of 3 treatment groups (untreated, Cy only and Cy and lysate/CpG).
Additional file 2: Figure S2. Tumor growth is delayed as the Cy dose
is increased. Mice were treated as in Fig. 2a. Cy only data from Fig. 3 is
graphed. Mice were followed for survival and euthanized when tumor
size reached 250 mm2. Each graph represents data combined from 2
separate experiments with 5 mice per group. Data was analyzed for
statistical significance using the log-rank (Mantel-Cox) test.
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